Trial · NCT03449147
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline | Placebo | 0.43 | 95% Confidence Interval 0.39 to 0.48 | Ratio | |
| Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline | Gefapixant 15 mg BID | 0.43 | 95% Confidence Interval 0.38 to 0.47 | Ratio | |
| Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline | Gefapixant 45 mg BID | 0.37 | 95% Confidence Interval 0.33 to 0.41 | Ratio | |
| Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up | Placebo | 349 | Participants | ||
| Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up | Gefapixant 15 mg BID | 373 | Participants | ||
| Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up | Gefapixant 45 mg BID | 399 | Participants | ||
| Number of Participants Who Discontinued a Study Drug Due to an AE | Placebo | 25 | Participants | ||
| Number of Participants Who Discontinued a Study Drug Due to an AE | Gefapixant 15 mg BID | 40 | Participants | ||
| Number of Participants Who Discontinued a Study Drug Due to an AE | Gefapixant 45 mg BID | 100 | Participants | ||
| Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline | Placebo | 0.42 | 95% Confidence Interval 0.38 to 0.47 | Ratio | |
| Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline | Gefapixant 15 mg BID | 0.41 | 95% Confidence Interval 0.37 to 0.46 | Ratio | |
| Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline | Gefapixant 45 mg BID | 0.36 | 95% Confidence Interval 0.32 to 0.40 | Ratio | |
| Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24 | Placebo | 70.1 | Percentage of Participants | ||
| Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24 | Gefapixant 15 mg BID | 75.9 | Percentage of Participants | ||
| Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24 | Gefapixant 45 mg | 76.8 | Percentage of Participants | ||
| Percentage of Participants With a ≤-30% Change From Baseline in 24-hour Coughs Per Hour at Week 24 | Placebo | 66.9 | Percentage of Participants | ||
| Percentage of Participants With a ≤-30% Change From Baseline in 24-hour Coughs Per Hour at Week 24 | Gefapixant 15 mg BID | 67.4 | Percentage of Participants | ||
| Percentage of Participants With a ≤-30% Change From Baseline in 24-hour Coughs Per Hour at Week 24 | Gefapixant 45 mg BID | 72.9 | Percentage of Participants | ||
| Percentage of Participants With ≤-1.3 Point Change From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24 | Placebo | 69.1 | Percentage of Participants | ||
| Percentage of Participants With ≤-1.3 Point Change From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24 | Gefapixant 15 mg BID | 74.8 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03449147/results